Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Indaptus Therapeutics, Inc. (INDP)
USD2.82
+0.19 (+7.22%)
US NASDAQ Healthcare Biotechnology
Address
3 Columbus Circle 10019
New York City, NY, US
New York City, NY, US
CEO
Junyi Dai
Website
indaptusrx.com
IPO
2015-08-04
CIK 1857044 ISIN US45339J2042
Description
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Intec Pharma Ltd | NTEC | 2021-04-20 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.82
+0.19 (+7.22%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.27
Float Shares
1.43M
Free Float %
81.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.14% | -15.43% | -53.91% | -12.15% | -29.96% | -45.36% | -85.44% | -97.23% | -99.58% | -99.98% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
2.82
DCF (Unlevered)
8.30
+194.2%
DCF (Levered)
8.81
+212.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-79.36
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-1,240.4% Q1'26: +52.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +3,458.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-89.7% ★ Q1'26: +17.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 750.0K (-100.0%)
|
—
est: 25.00M (-100.0%)
|
—
|
—
|
—
— – —
|
—
— – —
|
42.39M
42.39M – 42.39M
|
123.05M
123.05M – 123.05M
+190.3% YoY
|
| EBITDA |
-46.09M
|
-7.73M
|
-15.37M
|
-19.83M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-46.95M
|
-7.73M
|
-15.37M
|
-19.83M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-47.60M
est: -28.08B (+99.8%)
|
-7.71M
est: -1.22B (+99.4%)
|
-15.02M
est: -447.95M (+96.6%)
|
-20.85M
est: -20.09M (-3.8%)
|
-6.13M
-6.13M – -6.13M
+69.5% YoY
|
-4.27M
-4.27M – -4.27M
+30.3% YoY
|
763.2K
763.2K – 763.2K
+117.9% YoY
|
6.18M
6.18M – 6.18M
+710.1% YoY
|
| SGA |
7.43M
|
5.21M
|
8.11M
|
10.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-112.74
est: -3,001.60 (+96.2%)
|
-1.89
est: -130.34 (+98.5%)
|
-1.61
est: -47.88 (+96.6%)
|
-21.58
est: -20.79 (-3.8%)
|
-6.34
-6.34 – -6.34
+69.5% YoY
|
-4.42
-4.42 – -4.42
+30.3% YoY
|
0.79
0.79 – 0.79
+117.9% YoY
|
6.40
6.40 – 6.40
+710.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Michael J. Newman, Ph.D. | 1.39M | 25.70% | 1.36M | 26.8K | 1.36M | 26.8K | IN | States | 2021-08-13 | ↗ |
| 2 | Glen R. Anderson | 1.09M | 13.16% | 113.9K | 973.1K | 113.9K | 973.1K | IN | United States of America | 2022-07-08 | ↗ |
| 3 | A. Meckler | 875.7K | 6.90% | 875.7K | — | 875.7K | — | IN | States | 2024-11-26 | ↗ |
| 4 | Bio Investments, Inc. | 694.5K | 12.80% | — | 694.5K | — | 694.5K | IV | States (State of California) | 2021-08-13 | ↗ |
| 5 | Lee | 694.5K | 12.80% | — | 694.5K | — | 694.5K | IN | Korea (REPUBLIC OF KOREA) | 2021-08-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 15.7K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.20
Neutral
Ratio by volume
0.10
Bearish
Buys
6
Sells
5
Shares acquired
91.7K
Shares disposed
913.5K
Cash buys
—
Cash sales
2.00
Net activity
-821,800
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Lu Qinglai | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-23 | Yao Yun | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 41,991,000 | D | ↗ |
| 2026-03-23 | SINO LION VENTURES Ltd | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 38,895,000 | D | ↗ |
| 2026-03-23 | Lazar David E. | Director | S-Sale | D | Series AA Convertible Non-Redeemable Preferred Stock | 196,800 | 0.00 | — | 103,200 | D | ↗ |
| 2026-03-23 | Dai Junyi | Officer | — | — | Common Stock | 0 | 0.00 | — | 11,250,000 | D | ↗ |
| 2026-02-26 | McMurdo Matthew Charles | Director | — | — | Common Stock | 0 | 0.00 | — | 25,000 | D | ↗ |
| 2026-02-26 | Jabbour Jerome D | Director | A-Award | A | Option to Buy Common Stock | 25,000 | 2.06 | 51.5K | 25,000 | D | ↗ |
| 2026-02-11 | Meckler Jeffrey A | Director / Officer | D-Return | D | Warrants (right to buy) | 12,136 | 8.30 | 100.7K | 0 | D | ↗ |
| 2026-01-20 | Ben-Tzvi Avraham | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,100 | D | ↗ |
| 2026-01-08 | NATAN DAVID | Director | — | — | No securities are beneficially owned. | 0 | 0.00 | — | 0 | D | ↗ |
| 2026-01-07 | NATAN DAVID | Director | A-Award | A | Option to Buy Common Stock | 25,000 | 2.69 | 67.3K | 25,000 | D | ↗ |
| 2025-12-23 | Ben-Tzvi Avraham | Director | A-Award | A | Option to Buy Common Stock | 25,000 | 1.95 | 48.8K | 25,000 | D | ↗ |
| 2025-12-22 | Sassi Nir | Officer | A-Award | A | Common Stock | 26,758 | 2.03 | 54.3K | 26,758 | D | ↗ |
| 2025-12-22 | Newman Michael James | Director / Officer | A-Award | A | Common Stock | 52,204 | 2.03 | 106.0K | 101,074 | D | ↗ |
| 2025-12-22 | Meckler Jeffrey A | Director / Officer / 10% Owner | A-Award | A | Common Stock | 216,617 | 2.03 | 439.7K | 229,929 | D | ↗ |
| 2025-12-22 | Linscott Walt Addison | Officer | A-Award | A | Common Stock | 54,421 | 2.03 | 110.5K | 54,426 | D | ↗ |
| 2025-12-22 | Lazar David E. | Officer | — | — | Series AAA Convertible Preferred Stock | 105,000,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-22 | Ben-Tzvi Avraham | Director | — | — | Common Stock | 0 | 0.00 | — | 100 | D | ↗ |
| 2025-07-27 | Meckler Jeffrey A | Director / Officer | A-Award | A | Common Stock Warrants | 12,136 | 8.30 | 100.8K | 16,688 | D | ↗ |
| 2025-06-10 | Pomerantz Roger | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.33 | 9.9K | 30,000 | D | ↗ |
| 2025-06-10 | Martell Robert | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.33 | 4.1K | 12,500 | D | ↗ |
| 2025-06-10 | MADDALUNA ANTHONY J | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.33 | 4.1K | 12,500 | D | ↗ |
| 2025-06-10 | Karah Hila | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.33 | 4.1K | 12,500 | D | ↗ |
| 2025-06-10 | Hayes William B | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.33 | 4.1K | 12,500 | D | ↗ |
| 2025-06-10 | Gilbert Mark John | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.33 | 4.1K | 12,500 | D | ↗ |
| 2024-11-25 | Meckler Jeffrey A | Director / Officer | A-Award | A | Common stock | 42,553 | 1.18 | 50.0K | 202,859 | D | ↗ |
| 2024-10-09 | Waltzman Roger J. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.11 | 82.9K | 75,000 | D | ↗ |
| 2024-10-09 | Sassi Nir | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.11 | 82.9K | 75,000 | D | ↗ |
| 2024-10-09 | Newman Michael James | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.11 | 82.9K | 75,000 | D | ↗ |
| 2024-10-09 | Meckler Jeffrey A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.11 | 82.9K | 75,000 | D | ↗ |
| 2024-10-09 | Linscott Walt Addison | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.11 | 82.9K | 75,000 | D | ↗ |
| 2024-08-08 | Meckler Jeffrey A | Director / Officer | A-Award | A | Common Stock Warrants | 84,932 | 1.70 | 144.4K | 84,932 | — | ↗ |
| 2024-06-06 | Pomerantz Roger | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 2.63 | 78.9K | 30,000 | — | ↗ |
| 2024-06-06 | Martell Robert | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 2.63 | 32.9K | 12,500 | — | ↗ |
| 2024-06-06 | MADDALUNA ANTHONY J | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 2.63 | 32.9K | 12,500 | — | ↗ |
| 2024-06-06 | Karah Hila | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 2.63 | 32.9K | 12,500 | — | ↗ |
| 2024-06-06 | Hayes William B | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 2.63 | 32.9K | 12,500 | — | ↗ |
| 2024-06-06 | Gilbert Mark John | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 2.63 | 32.9K | 12,500 | — | ↗ |
| 2024-01-22 | Waltzman Roger J. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.74 | 130.5K | 75,000 | — | ↗ |
| 2024-01-22 | Sassi Nir | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.74 | 69.6K | 40,000 | — | ↗ |
| 2024-01-22 | Newman Michael James | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 43,250 | 1.74 | 75.3K | 43,250 | — | ↗ |
| 2024-01-22 | Meckler Jeffrey A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.74 | 174.0K | 100,000 | — | ↗ |
| 2024-01-22 | Linscott Walt Addison | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.74 | 130.5K | 75,000 | — | ↗ |
| 2023-08-14 | Anderson Glen R. | 10% Owner | P-Purchase | A | Common Stock | 23,934 | 2.34 | 56.0K | 1,190,400 | — | ↗ |
| 2023-08-11 | Anderson Glen R. | 10% Owner | P-Purchase | A | Common Stock | 35,064 | 2.12 | 74.3K | 1,166,466 | — | ↗ |
| 2023-08-10 | Anderson Glen R. | 10% Owner | P-Purchase | A | Common Stock | 44,354 | 1.94 | 86.0K | 1,131,402 | — | ↗ |
| 2023-08-07 | Waltzman Roger J. | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.85 | 166.5K | 90,000 | — | ↗ |
| 2023-05-25 | Pomerantz Roger | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.82 | 54.6K | 30,000 | — | ↗ |
| 2023-05-25 | MADDALUNA ANTHONY J | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.82 | 22.8K | 12,500 | — | ↗ |
| 2023-05-25 | Karah Hila | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.82 | 22.8K | 12,500 | — | ↗ |
| 2023-05-25 | Hayes William B | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.82 | 22.8K | 12,500 | — | ↗ |
| 2023-05-25 | Gilbert Mark John | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 1.82 | 22.8K | 12,500 | — | ↗ |
| 2023-02-13 | Martell Robert | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.71 | 34.2K | 20,000 | — | ↗ |
| 2023-01-18 | Sassi Nir | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-18 | Newman Michael James | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 43,250 | 0.00 | — | 43,250 | — | ↗ |
| 2023-01-18 | Meckler Jeffrey A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-18 | Linscott Walt Addison | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-01 | Litchev Boyan Vesselinov | Officer | P-Purchase | A | Common Stock | 500 | 1.87 | 935.45 | 1,150 | — | ↗ |
| 2022-11-22 | Litchev Boyan Vesselinov | Officer | P-Purchase | A | Common Stock | 500 | 1.83 | 915.00 | 650 | — | ↗ |
| 2022-11-21 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common stock | 9,600 | 1.90 | 18.2K | 75,374 | — | ↗ |
| 2022-11-18 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common stock | 400 | 1.76 | 705.48 | 65,774 | — | ↗ |
| 2022-09-30 | Pomerantz Roger | Director | A-Award | A | Stock Option (right to buy) | 81,000 | 0.00 | — | 81,000 | — | ↗ |
| 2022-09-30 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-09-30 | MADDALUNA ANTHONY J | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-09-30 | Karah Hila | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-09-30 | Hayes William B | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-09-30 | Gilbert Mark John | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-09-08 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common stock | 10,308 | 2.80 | 28.9K | 65,374 | — | ↗ |
| 2022-09-07 | Linscott Walt Addison | Officer | P-Purchase | A | Common stock | 150 | 2.62 | 393.00 | 150 | — | ↗ |
| 2022-09-06 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common stock | 8,632 | 2.57 | 22.2K | 55,066 | — | ↗ |
| 2022-06-27 | Anderson Glen R. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 973,130 | — | ↗ |
| 2022-06-06 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common stock | 19,727 | 2.63 | 51.9K | 45,374 | — | ↗ |
| 2022-03-02 | Litchev Boyan Vesselinov | Officer | P-Purchase | A | Common Stock | 50 | 4.09 | 204.63 | 150 | — | ↗ |
| 2022-02-25 | Sassi Nir | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 4.18 | 250.8K | 60,000 | — | ↗ |
| 2022-02-01 | Newman Michael James | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 14,130 | 5.00 | 70.7K | 1,368,356 | — | ↗ |
| 2022-02-01 | Litchev Boyan Vesselinov | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 4.97 | 447.3K | 90,000 | — | ↗ |
| 2022-01-31 | Newman Michael James | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 5,870 | 5.00 | 29.4K | 1,382,486 | — | ↗ |
| 2022-01-31 | Litchev Boyan Vesselinov | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-26 | Newman Michael James | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 43,350 | 4.90 | 212.4K | 43,350 | — | ↗ |
| 2022-01-26 | Meckler Jeffrey A | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 4.90 | 980.0K | 200,000 | — | ↗ |
| 2022-01-26 | Linscott Walt Addison | Officer | A-Award | A | Stock Option (right to buy) | 45,850 | 4.90 | 224.7K | 45,850 | — | ↗ |
| 2021-12-01 | Gilbert Mark John | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.35 | 107.0K | 20,000 | — | ↗ |
| 2021-11-29 | Gilbert Mark John | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-18 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common Stock | 11,187 | 5.82 | 65.1K | 25,647 | — | ↗ |
| 2021-09-14 | Meckler Jeffrey A | Director / Officer | P-Purchase | A | Common Stock | 12,000 | 7.00 | 84.0K | 14,460 | — | ↗ |
| 2021-08-04 | Sassi Nir | Officer | A-Award | A | Stock Option (right to buy) | 35,000 | 8.87 | 310.5K | 35,000 | — | ↗ |
| 2021-08-04 | Pomerantz Roger | Director | A-Award | A | Stock Option (right to buy) | 41,000 | 8.87 | 363.7K | 41,000 | — | ↗ |
| 2021-08-04 | O'CALLAGHAN BRIAN | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 8.87 | 122.0K | 13,750 | — | ↗ |
| 2021-08-04 | Newman Michael James | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 290,000 | 8.87 | 2.57M | 290,000 | — | ↗ |
| 2021-08-04 | Meckler Jeffrey A | Director / Officer | A-Award | A | Stock Option (right to buy) | 375,000 | 8.87 | 3.33M | 375,000 | — | ↗ |
| 2021-08-04 | MADDALUNA ANTHONY J | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 8.87 | 122.0K | 13,750 | — | ↗ |
| 2021-08-04 | Linscott Walt Addison | Officer | A-Award | A | Stock Option (right to buy) | 210,000 | 8.87 | 1.86M | 210,000 | — | ↗ |
| 2021-08-04 | Lee Hoonmo | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 8.87 | 122.0K | 13,750 | — | ↗ |
| 2021-08-04 | Karah Hila | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 8.87 | 122.0K | 13,750 | — | ↗ |
| 2021-08-04 | Hayes William B | Director | A-Award | A | Stock Option (right to buy) | 13,750 | 8.87 | 122.0K | 13,750 | — | ↗ |
| 2021-08-03 | O'CALLAGHAN BRIAN | Director | — | D | Stock Option (right to buy) | 20,926 | 2.80 | 58.6K | 0 | — | ↗ |
| 2021-08-03 | Newman Michael James | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,388,356 | — | ↗ |
| 2021-08-03 | Lee Hoonmo | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 694,522 | — | ↗ |
| 2021-07-23 | Sassi Nir | Officer | — | D | Stock Option (right to buy) | 625 | 436.80 | 273.0K | 0 | — | ↗ |
| 2021-07-23 | Pomerantz Roger | Director | — | D | Stock Option (right to buy) | 250 | 388.60 | 97.2K | 0 | — | ↗ |
| 2021-07-23 | Meckler Jeffrey A | Director / Officer | — | D | Stock Option (right to buy) | 813 | 425.60 | 346.0K | 0 | — | ↗ |
| 2021-07-23 | MADDALUNA ANTHONY J | Director | — | D | Common Stock | 0 | 0.00 | — | 670 | — | ↗ |
| 2021-07-23 | Linscott Walt Addison | Officer | — | D | Stock Option (right to buy) | 1,125 | 34.30 | 38.6K | 0 | — | ↗ |
| 2021-07-23 | Karah Hila | Director | — | D | Stock Option (right to buy) | 281 | 480.00 | 134.9K | 0 | — | ↗ |
| 2021-07-23 | Hayes William B | Director | — | D | Stock Option (right to buy) | 500 | 24.60 | 12.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.75M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jeffrey A. Meckler, Co-Chief Executive Officer | 458.6K | — | — | — | 297.5K | 1.44M | 2.20M | 0.00% | ↗ |
| 2 | 2025 | Walt A. Linscott, Esq., Chief Operating Officer | 491.0K | — | — | — | 245.5K | 1.22M | 1.95M | 0.00% | ↗ |
| 3 | 2025 | Michael J. Newman Chief Science Officer | 363.1K | — | — | — | 235.5K | 1.09M | 1.69M | 0.00% | ↗ |
| 4 | 2024 | Jeffrey A. Meckler, Chief Executive Office | 575.0K | — | — | 219.4K | 287.5K | 75.3K | 1.16M | 18.96% | ↗ |
| 5 | 2024 | Jeffrey A. Meckler, Co-Chief Executive Officer | 575.0K | — | — | 219.4K | 287.5K | 75.3K | 1.16M | 18.96% | ↗ |
| 6 | 2024 | Walt A. Linscott, Esq., Chief Operating Officer | 475.0K | — | — | 182.2K | 237.5K | 75.7K | 970.4K | 18.77% | ↗ |
| 7 | 2024 | Roger Waltzman, M.D. Chief Medical Officer | 500.0K | — | — | 182.2K | 200.0K | 46.7K | 928.9K | 19.61% | ↗ |
| 8 | 2024 | Michael J. Newman Chief Science Officer | 455.0K | — | — | 134.8K | 227.5K | 17.5K | 834.8K | 16.15% | ↗ |
| 9 | 2023 | Jeffrey A. Meckler, Chief Executive Office ) | 565.0K | — | — | 134.2K | 223.2K | 78.9K | 1.00M | 13.41% | ↗ |
| 10 | 2023 | Jeffrey A. Meckler, Chief Executive Office | 565.0K | — | — | 134.2K | 223.2K | 78.9K | 1.00M | 13.41% | ↗ |
| 11 | 2023 | Walt A. Linscott, Esq., Chief Operating Officer | 425.0K | — | — | 53.7K | 212.5K | 78.9K | 770.0K | 6.97% | ↗ |
| 12 | 2023 | Michael J. Newman, Ph.D. Chief Scientific Officer | 442.0K | — | — | 58.1K | 198.9K | 19.1K | 718.0K | 8.08% | ↗ |
| 13 | 2023 | Roger Waltzman, M.D. Chief Medical Officer | 196.7K | 20.0K | — | 140.8K | 196.0K | 32.6K | 586.2K | 24.02% | ↗ |
| 14 | 2022 | Jeffrey A. Meckler, Chief Executive Office ) | 552.0K | — | — | 792.2K | 276.0K | 60.3K | 1.68M | 47.14% | ↗ |
| 15 | 2022 | Jeffrey A. Meckler, Chief Executive Officer | 552.0K | — | — | 792.2K | 276.0K | 60.3K | 1.68M | 47.14% | ↗ |
| 16 | 2022 | Boyan Litchev, M.D., Former Chief Medical Officer | 391.2K | 75.0K | — | 361.5K | 125.0K | 325.0K | 1.28M | 28.29% | ↗ |
| 17 | 2022 | Walt A. Linscott, Esq., Chief Operating Officer | 405.0K | — | — | 181.6K | 202.5K | 59.1K | 848.2K | 21.41% | ↗ |
| 18 | 2021 | Jeffrey A. Meckler, Chief Executive Officer | 540.0K | 200.0K | — | 2.64M | 166.7K | 52.1K | 3.59M | 73.32% | ↗ |
| 19 | 2021 | Walt A. Linscott, Esq., Chief Operating Officer | 366.5K | 175.0K | — | 1.48M | 126.3K | 51.3K | 2.19M | 67.24% | ↗ |
| 20 | 2021 | Jeffrey Meckler Chief Executive Officer | 540.0K | 200.0K | — | 453.4K | 166.7K | 52.1K | 1.41M | 32.11% | ↗ |
| 21 | 2021 | Walt A. Linscott, Esq., Chief Business Officer | 366.5K | 175.0K | — | 372.5K | 126.3K | 51.3K | 1.09M | 34.12% | ↗ |
| 22 | 2021 | Michael J. Newman Chief Scientific Officer | 291.5K | 75.0K | — | 283.0K | 100.5K | 1.8K | 851.9K | 33.23% | ↗ |
| 23 | 2020 | Jeffrey Meckler Chief Executive Officer | 540.0K | — | — | 268.1K | 210.6K | 47.5K | 1.07M | 25.15% | ↗ |
| 24 | 2020 | Walt A. Linscott, Esq., Chief Business Officer | 340.0K | — | — | 231.3K | 170.0K | 47.9K | 789.2K | 29.30% | ↗ |
| 25 | 2020 | Michael J. Newman Chief Scientific Officer | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeffrey A. Meckler | Co-CEO & Director | 2M | male |
| Walt Addison Linscott | Chief Operating Officer | 2M | male |
| Michael J. Newman | Founder, Chief Scientific Officer & Director | 2M | — |
| Nir Sassi | Chief Financial Officer, Secretary & Treasurer | 378.5K | male |
| David Elliot Lazar | Chairman & Co-CEO | — | male |
| Junyi Dai | CEO & Chairman | — | male |
| Yu Ding | Chief Financial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INDP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
